Delivery Order SPE2DB22D3501-SPE2DB25FWJ20

Award Date 7/9/25
Potential Completion Date 7/10/25
Potential Value $9.8K
Ultimate Awardee
Not listed
Federal Contract Vehicle
Set-Aside Type
No Set-Aside Used
Extent Competed
Full and Open Competition
Major Defense Program
Not listed
Pricing Type
Firm Fixed Price
Place of Performance
Conshohocken, PA 19428, USA
Solicitation Procedures
Negotiated Proposal / Quote
Number Of Offers Received
Not listed
Legislative Mandate
Not listed
National Interest Action
Not listed
Research Type
Not listed
Primary Consortia Member
Not listed
Similar Awards
This is a delivery order awarded by the Defense Logistics Agency (DLA) to AmerisourceBergen Drug Corporation, a major pharmaceutical distributor, for the supply of BIMZELX 320 MG/2 ML AUTOINJECT 2ML, a specialty pharmaceutical product. The contract is a Firm Fixed Price, non-set-aside agreement with a ceiling value of $13,795.65 and a period of performance through June 10, 2025. AmerisourceBergen Drug Corporation holds a significant Indefinite Delivery Contract (IDC) with the DLA Troop Support...
This is a federal contract award to Amerisourcebergen Drug Corp, a major pharmaceutical distributor and healthcare solutions provider, by the Defense Logistics Agency (DLA). The contract is a Delivery Order valued at $15,960.69 and has a firm fixed price pricing type. It is for the supply of BIMZELX 160 MG/ML AUTOINJECTOR medical products, with an ultimate completion date of July 14, 2025. The contract is not set aside and is open to full and open competition. Amerisourcebergen Drug Corp holds a...
This is a federal contract award to Amerisourcebergen Drug Corp, a major pharmaceutical distributor and healthcare solutions provider. The contract, valued at $9,855.21, is a delivery order with a firm fixed price. The funding agency is the Defense Logistics Agency, a defense agency. The contract is for the supply of BIMZELX 320 MG/2 ML AUTOINJECT 2ML, a pharmaceutical product. It has an ultimate completion date of June 24, 2025. The contract is not designated as a set-aside. Amerisourcebergen...
This is a federal contract award from the Defense Logistics Agency (DLA) to AmerisourceBergen Drug Corp, a major pharmaceutical distributor. The $8,632.69 Firm Fixed Price Delivery Order is for the supply of BIMZELX 160 MG/ML AUTOINJECTORML, a medical product. The contract has an ultimate completion date of March 7, 2025. This award is part of a larger Indefinite Delivery Contract (IDC) that AmerisourceBergen holds with the DLA Troop Support Medical, valued at $999,999,999 and running through...
This is a $20,936.95 firm fixed-price delivery order contract awarded by the Defense Logistics Agency (DLA) to Amerisourcebergen Drug Corp, a major pharmaceutical distributor and healthcare solutions provider. The contract is for the delivery of BIMZELX 320 MG/2 ML AUTOINJECT 2ML medical products. The contract has a performance period through June 30, 2025 and is not designated as a set-aside. Amerisourcebergen Drug Corp holds a significant $999,999,999.00 Indefinite Delivery Contract (IDC) with...
This federal contract award, valued at $25,549.28, was issued by the Defense Logistics Agency (DLA) to Amerisourcebergen Drug Corp, a major pharmaceutical distributor and healthcare solutions provider. The contract is a delivery order for the medication BIMZELX 160 MG/ML AUTOINJECTORML, with a performance period ending on May 2, 2025. The contract is a firm fixed-price agreement and is not designated as a set-aside. Amerisourcebergen Drug Corp holds a significant Indefinite Delivery Contract...
This is a federal delivery order contract awarded by the Defense Logistics Agency (DLA) to Amerisourcebergen Drug Corp, a major pharmaceutical distributor and healthcare solutions provider. The contract is for the delivery of BIMZELX 320 MG/2 ML AUTOINJECT 2ML medical products, with a ceiling value of $29,565.63 and a performance period ending on July 14, 2025. The contract is not set-aside and was awarded on a firm fixed-price basis. Amerisourcebergen Drug Corp holds a significant Indefinite...
This is a $11,677.57 firm fixed-price delivery order contract awarded to Amerisourcebergen Drug Corp, a major pharmaceutical distributor, by the Defense Logistics Agency (DLA). The contract is for the supply of BIMZELX 160 MG/ML AUTOINJECTORML, a medical product, with a period of performance through July 8, 2025. Amerisourcebergen Drug Corp holds a significant $999,999,999.00 Indefinite Delivery Contract (IDC) with the DLA Troop Support Medical, designated as SPE2DX, that provides a...
This is a federal contract award from the Defense Logistics Agency (DLA) to AmerisourceBergen Drug Corp, a major pharmaceutical distributor and healthcare solutions provider. The contract is a Delivery Order with a Firm Fixed Price of $9,407.04 and an Ultimate Completion Date of April 9, 2025. The contract is for the supply of BIMZELX 160 MG/ML AUTOINJECTORML, a pharmaceutical product, and does not have a set-aside designation. AmerisourceBergen holds a significant Indefinite Delivery Contract...
This federal contract award was issued by the Defense Logistics Agency (DLA) to AmerisourceBergen Drug Corp, a major pharmaceutical distributor and healthcare solutions provider. The $11,292.36 Firm Fixed Price Delivery Order (SPE2DB22D2211) is for the supply of BIMZELX 160 MG/ML AUTOINJECTOR, a specialty medication, with a completion date of January 16, 2025. AmerisourceBergen holds a significant $999,999,999 Indefinite Delivery Contract (IDC) with the DLA Troop Support Medical, which serves as...
  • SPE2DB22D3501
    Indefinite Delivery Contract
  • SPE2DB22D3501-SPE2DB25FWJ20
    Delivery Order

This is a federal contract award to Amerisourcebergen Drug Corp, a major pharmaceutical distributor, by the Defense Logistics Agency (DLA) for the delivery of BIMZELX 320 MG/2 ML SYRINGE 2ML. The contract is a delivery order with a firm fixed price of $9,783.88 and a completion date of July 10, 2025. The contract is not set aside for any specific business category. Amerisourcebergen Drug Corp holds a significant Indefinite Delivery Contract (IDC) with the DLA Troop Support Medical, valued at $999,999,999.00, which provides a comprehensive global pharmaceutical support vehicle with a performance period extending through December 2026. This award is likely part of the company's broader supply of pharmaceutical and medical products to various government agencies, including the Defense Health Agency and U.S. Coast Guard, to support military and veteran healthcare systems.

Generated 10/12/25, 1:01 AM